Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Consumer IPOs from Snap to Uber have been disappointing and serve as a reminder that private investors are making all the money.Technologyread more
China's currency has been an important barometer for progress in U.S.-Chinese trade talks, and right now it's signaling things aren't going well.Market Insiderread more
The company's comments Friday come after the White House said U.S.Trade Representative Robert Lighthizer will "address the threatened impairment" of national security from...Autosread more
While the prolonged fight has been devastating to an already-struggling agriculture industry, there's little indication Trump is paying a political price.Traderead more
Some analysts see streaming services like Netflix becoming hindered by one of the things that made them so popular in the first place — binge watching.Entertainmentread more
The 2019 PGA Championship wraps up on Sunday, May 19. Here's how much money the champion will earn.Earnread more
Apple CEO Tim Cook was the commencement speaker at Tulane University Saturday. In his speech, the tech executive focused on the importance of addressing climate change and...Power Playersread more
There is a shortfall of cybersecurity workers that could reach as high as 3.5 million unfilled roles by 2021. A start-up called Synack provides crowdsourced security, and...CNBC Disruptor 50read more
Yardeni Research's Edward Yardeni recommends investing in U.S. companies with exposure to China.Trading Nationread more
CNBC and SurveyMonkey's latest small business optimism index echoes that sentiment, finding 52 percent of small businesses say it's harder to find workers today than it was a...US Economyread more
Amazon is ramping up conversations with a group of drug middlemen known as pharmacy benefits managers or PBMs, according to analysts from Leerink Partners. PBMs are a critical part of the drug supply chain, as they negotiate prices with drug manufacturers on one end, and manage pharmacy benefits for insurers on the other.
The report, which was previously spotted by Axios, also outlines the "disruptive" potential posed by Amazon across the multibillion dollar pharmacy benefits and pharmacy arena.
Citing an anonymous analyst, the report states that Amazon may "indeed be in conversations with some middle-market PBMs now, in an effort to get into various contract arrangements."
That suggests that Amazon is a "bigger threat" than many expect, but that it won't be right away. Leerink estimates that it will take about 18 to 24 months for Amazon to get pharmacy licenses in all 50 states.
CNBC reported in May that Amazon was looking to hire a general manager to lead its pharmacy business. And that it had already hired Mark Lyons from Premera Blue Cross, a local insurer, who was tasked with building an internal PBM.
In the ensuing months, analysts and investors asked players across the supply chain were asked about the Amazon threats. Some described Amazon has a potential partner, while others were skeptical that the e-commerce company would move into a highly-regulated space.
-- CNBC's Michael Bloom contributed to this report.